Casdin Capital
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry.
Business Model:
Revenue: $12.9M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Casdin Capital Information
Geographic Data
Address: 1350 Avenue of the Americas
City: New York
State: NY
Zip: 10019
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
7,325,186Website Global Rank
538Website Monthly Traffic
Twitter Followers
Description
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management.
Contact Phone:
+12128975430
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2020 | Genome Medical | Series B | 0 |
| 3/2021 | Amunix | Series B | 117M |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 3/2021 | Palamedrix | Seed Round | 0 |
| 6/2014 | Omniox | Venture Round | 6.6M |
| 4/2021 | SeQure DX | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 1/2022 | DNA Script | Series C | 0 |
| 12/2017 | Neon Therapeutics | Series B | 36M |
| 1/2018 | Genapsys | Series C | 32.5M |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 10/2018 | Genomatica | Equity | 90M |
| 5/2019 | Foghorn Therapeutics | Venture Round | 61M |
| 7/2020 | GeneMatters | Venture Round | 10.2M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 1/2021 | Auron Therapeutics | Seed Round | 0 |
| 11/2017 | Arzeda | Series A | 3.2M |
| 3/2021 | Leyden Labs | Series A | 47.1M |
| 9/2020 | Invetx | Series A | 0 |
| 12/2013 | Invitae | Series E | 0 |
| 4/2021 | Apton Biosystems | Series A | 24.6M |
| 4/2020 | Cerevance | Series B | 65M |
| 7/2018 | Alector | Series E | 133M |
| 7/2021 | TMRW Life Sciences | Series C | 105M |
| 10/2015 | 23andMe | Series E | 115M |
| 4/2020 | Character Biosciences | Seed Round | 6M |
| 5/2018 | Lyra Health | Series B | 0 |
| 1/2016 | Flatiron Health | Series C | 175M |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 4/2018 | Vineti | Series B | 33.5M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 10/2017 | Helix | Venture Round | 20M |
| 4/2018 | Magenta Therapeutics | Series C | 0 |
| 4/2015 | Voyager Therapeutics | Series B | 0 |
| 5/2021 | Vedere Bio ll | Series A | 0 |
| 6/2020 | Verve Therapeutics | Series A | 63M |
| 5/2022 | Character Biosciences | Series A | 0 |
| 12/2021 | ONI | Series B | 75M |
| 4/2023 | Function Oncology | Series A | 28M |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 8/2021 | NanoCellect Biomedical | Series D | 0 |
| 7/2018 | ONI | Series A | 24M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 10/2020 | Vineti | Series C | 33M |
| 2/2020 | Vineti | Series C | 35M |
| 1/2022 | Leyden Labs | Series B | 140M |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 1/2021 | FogPharma | Series C | 107M |
| 3/2022 | Deepcell | Series B | 0 |
| 10/2021 | Loop Medical | Series A | 0 |
| 1/2021 | Earli | Series A | 40M |
| 4/2021 | C2i Genomics | Series B | 0 |
| 9/2020 | ONI | Series A | 5M |
| 12/2021 | Depixus | Series A | 0 |
| 1/2021 | EQRx | Series B | 500M |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 10/2020 | A2 Biotherapeutics | Series B | 71.5M |
| 9/2022 | LetsGetChecked | Series D | 0 |
| 7/2020 | DNA Script | Series B | 50M |
| 3/2020 | Kallyope | Series C | 112M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 6/2021 | 23andMe | Post-IPO Equity | 250M |
| 2/2018 | Generation Bio | Series B | 100M |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 11/2020 | SomaLogic | Series A | 0 |
| 1/2021 | Paige | Series C | 125M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 10/2020 | LianBio | Series A | 0 |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 3/2021 | Tenaya Therapeutics | Series C | 106M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 1/2023 | Asimov | Series B | 175M |
| 3/2022 | InnoSIGN | Series A | 8.1M |
| 10/2021 | Thyme Care | Venture Round | 22M |
| 10/2020 | Oxford Nanopore Technologies | Series H | 0 |
| 12/2013 | Ignyta | Venture Round | 54M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 3/2022 | Arzeda | Series B | 0 |
| 1/2014 | Blueprint Medicines | Series B | 25M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 5/2021 | Flare Therapeutics | Series A | 82M |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 12/2021 | Nomic Bio | Series A | 17M |
| 1/2014 | Fabric Genomics (formerly Omicia) | Series A | 6.8M |
| 3/2020 | Lyra Health | Series C | 0 |
| 9/2018 | Prominex | Series A | 4M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 8/2020 | Tango Therapeutics | Venture Round | 50M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 10/2021 | ShouTi | Series B | 0 |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 5/2022 | Invetx | Series B | 0 |
| 7/2021 | Genomatica | Series C | 0 |
| 2/2021 | Imagen Technologies | Series C | 75M |
| 12/2020 | PanThera CryoSolutions Inc. | Equity | 2M |
| 1/2023 | iVexSol | Series A | 23.8M |
| 9/2019 | iVexSol | Seed | 2M |
| 12/2020 | iVexSol | Series A | 13M |
| 1/2022 | Xcell Biosciences | Series B | 27.5M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 1/2020 | EQRx | Series A | 200M |
| 9/2017 | 23andMe | Series F | 0 |
| 2/2021 | Orchard Therapeutics | Post-IPO Equity | 150M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 12/2022 | Vector Biomed | Venture Round | 15M |
| 9/2018 | Fulcrum Therapeutics | Series B | 80M |
| 6/2019 | Codexis | Post-IPO Equity | 50M |
| 12/2020 | Mnemo Therapeutics | Seed Round | - |
| 3/2000 | Spotfire | Series C | 15M |
| 1/2019 | Singular Bio | Venture Round | 6.6M |
| 4/2021 | Multiply Labs | Series A | 20M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 6/2020 | C2i Genomics | Series A | 12M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 3/2017 | Peloton Therapeutics | Series D | 22.2M |
| 11/2019 | Umoja Biopharma | Seed Round | - |
| 1/2020 | Wamberg Genomic Advisors | Seed Round | - |
| 1/2016 | Syros Pharmaceuticals | Series C | 40M |
| 1/2020 | Generation Bio | Series C | 110M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 11/2021 | Beacon Biosignals | Series A | 27M |
| 6/2020 | Goldfinch Biopharma | Series B | 100M |
| 12/2020 | CANbridge Pharmaceuticals | Series E | 0 |
| 1/2022 | Septerna | Series A | 100M |
| 5/2019 | Thrive Earlier Detection | Series A | 110M |
| 10/2014 | Invitae | Series F | 0 |
| 2/2021 | Notch Therapeutics | Series A | 85M |
| 12/2021 | Apella Technology | Series A | 0 |
| 3/2021 | Komodo Health | Series E | 220M |
| 3/2022 | Molecular Assemblies | Series B | 0 |
| 8/2021 | T-knife | Series B | 110M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 6/2021 | LetsGetChecked | Series D | 150M |
| 5/2021 | Dyno Therapeutics | Series A | 100M |
| 3/2022 | Volta Labs | Series A | 0 |
| 3/2020 | Amunix | Series A | 0 |
| 7/2022 | Auron Therapeutics | Series A | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 9/2018 | Imagen Technologies | Series B | 40M |
| 11/2021 | Stilla Technologies | Debt Financing | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 9/2012 | Foundation Medicine | Series B | 42.5M |
| 5/2018 | PACT Pharma | Series B | 95M |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 1/2020 | PACT Pharma | Series C | 0 |
| 5/2020 | Insitro | Series B | 143M |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 8/2021 | Genome Medical | Series C | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 4/2021 | Exscientia | Series D | 225M |
| 10/2019 | Tenaya Therapeutics | Series B | 92M |
| 10/2020 | Cedilla Therapeutics | Series B | 57.6M |
| 9/2021 | TrialSpark | Series C | 156M |
| 1/2022 | Verana Health | Series E | 0 |
| 4/2021 | Treeline Biosciences | Series A | - |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 5/2017 | Magenta Therapeutics | Series B | 0 |
| 12/2017 | Relay Therapeutics | Series B | 63M |
| 8/2019 | ORIC Pharmaceuticals | Series D | 0 |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 9/2020 | Recursion Pharmaceuticals | Series D | 239M |
| 12/2021 | Exai Bio | Series A | 67.5M |
| 3/2017 | 908 Devices | Series D | 20M |
| 4/2020 | Tango Therapeutics | Series B | 60M |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 4/2015 | MyoKardia | Series B | 0 |
| 7/2021 | Prime Medicine | Series B | 200M |
| 8/2014 | MyoKardia | Venture Round | 0 |
| 12/2020 | Octave Bioscience | Series B | 32M |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 4/2018 | Revolution Medicines | Series B | 56M |
| 9/2021 | Hexagon Bio | Series B | 61M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 8/2022 | Idrx | Series A | 0 |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2020 | NiKang Therapeutics | Series B | 50M |
| 10/2021 | Structure Therapeutics | Series B | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 2/2020 | Verana Health | Series D | 100M |
| 3/2021 | Insitro | Series C | 400M |
| 11/2022 | FogPharma | Series D | 0 |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 3/2023 | Flare Therapeutics | Series B | 0 |
| 11/2021 | Lunit | Venture Round | 0 |
| 3/2021 | Absci | Venture Round | 0 |
| 1/2023 | Nest | Seed Round | 0 |
| 10/2020 | Absci | Series E | 70M |
| 9/2019 | Sexton Biotechnologies | Venture Round | 0 |
| 4/2019 | 908 Devices | Series E | 17.5M |
| 8/2022 | Idrx | Series A | 0 |
| 7/2022 | Auron Therapeutics | Series A | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | Character Biosciences | Series A | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Invetx | Series B | 0 |
| 3/2022 | Arzeda | Series B | 0 |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 3/2022 | InnoSIGN | Series A | 0 |
| 3/2022 | Deepcell | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
